A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
March 17th, 2023
2.7K views
The present protocol describes a detailed, real-time NIR-II fluorescence imaging operation of a mouse using a NIR-II optics imaging device.
Overview
This protocol outlines a real-time NIR-II fluorescence imaging operation for mice using a specialized imaging device. It highlights the significance of high-resolution imaging in vascular and tumor studies.
Key Study Components
Area of Science
- Neuroscience
- Biomedical Imaging
- Fluorescence Imaging
Background
- NIR-II imaging allows for deeper visualization in living subjects.
- It is effective for studying vascular diseases and cancer.
- This technique enhances opportunities for biomedical research.
- Commercially available materials are used to prepare for imaging.
Purpose of Study
- To demonstrate the use of NIR-II fluorescence imaging in live mice.
- To provide a detailed protocol for researchers.
- To improve imaging techniques for vascular and tumor analysis.
Methods Used
- Preparation of the imaging setup with black cardboard.
- Placement of the sample for optimal imaging.
- Selection of appropriate filters for imaging.
- Adjustment of platform height using touchscreen controls.
Main Results
- Successful high-resolution imaging of vascular structures.
- Effective visualization of tumor environments.
- Demonstration of the imaging device's capabilities.
- Potential applications in clinical settings.
Conclusions
- NIR-II fluorescence imaging is a valuable tool for biomedical research.
- It provides insights into vascular diseases and cancer.
- The protocol can be utilized by researchers for various applications.
Frequently Asked Questions
What is NIR-II fluorescence imaging?
NIR-II fluorescence imaging is a technique that allows for high-resolution imaging of biological tissues using near-infrared light.
How does this imaging technique benefit cancer research?
It enables deeper visualization of tumors and vascular structures, improving the understanding of cancer progression.
What materials are needed for the imaging setup?
Commercially available black cardboard is used to prepare the imaging device.
Can this method be applied in clinical settings?
Yes, the technique has potential applications in clinical diagnostics and research.
What adjustments are necessary for optimal imaging?
Adjustments include selecting the appropriate filter and platform height for the sample.
Is training required to use the imaging device?
Yes, familiarity with the device's controls and setup is essential for effective use.
Executive Industry Relevance
NIR-II fluorescence imaging with the HLY1 probe enables high-resolution, deep-tissue visualization of vascular and tumor structures, addressing a critical need for sensitive and quantitative imaging in preclinical research. This capability enhances predictive confidence in disease models and supports translational continuity from discovery through preclinical validation. The approach is strategically positioned to improve biological de-risking and inform portfolio advancement decisions in oncology and vascular disease pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables precise visualization of vascular and tumor microenvironments for hypothesis testing.
- Supports functional target validation by providing real-time, quantitative imaging data.
- Facilitates mechanistic de-risking through high-sensitivity detection of biological changes.
- Improves predictive confidence for early-stage asset triage.
Screening & Assay Development
- Provides validated imaging outputs for downstream assay development workflows.
- Enables reproducible, quantitative measurement of probe distribution and signal intensity.
- Supports standardization of imaging protocols for scalable compound evaluation.
- Prepares robust biological systems for high-content screening applications.
Translational & Preclinical Research
- Aligns imaging outputs with disease-relevant models for translational biomarker development.
- Ensures continuity of quantitative imaging from discovery through preclinical validation.
- Supports risk-adjusted advancement decisions based on in vivo imaging data.
- Provides mechanistic insights into probe behavior and disease targeting.
Pipeline & Workflow Integration
The HLY1 NIR-II imaging workflow integrates from early discovery through preclinical research, enabling seamless transition between hypothesis testing, assay development, and translational validation.
- Discovery Biology: Supports pathway clarification and biological de-risking via high-resolution imaging of vascular and tumor structures.
- Screening: Delivers quantitative, reproducible imaging outputs suitable for assay standardization and compound evaluation.
- Analytics: Provides robust fluorescence intensity measurements and spatial resolution for comparative analysis.
- Translational Research: Aligns imaging data with disease models to inform biomarker strategies and preclinical decisions.
- Enterprise Reuse: Establishes a reusable imaging platform for diverse disease models and research programs.
Operational & Enterprise Impact
- Scientific Value: Enhances predictive confidence and target validation through deep-tissue, high-sensitivity imaging.
- Operational Value: Standardizes imaging protocols for reproducibility and scalability across studies.
- Strategic Value: Informs go/no-go decisions and reduces late-stage biological risk with quantitative imaging data.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of assets based on robust in vivo imaging evidence.
Implementation Considerations
- Requires expertise in fluorescence imaging and probe preparation.
- Needs access to NIR-II optical imaging systems and analytical software.
- Demands cross-team standardization of imaging protocols and data analysis.
- Adaptation may be necessary for different animal models or disease contexts.
- Imaging depth and probe distribution may vary with tissue type and experimental design.
Biopharma FAQs
Why does null hypothesis testing matter for NIR-II probe target validation?
Null hypothesis testing ensures that observed imaging signals from HLY1 are statistically significant and not due to background or random effects. This rigor is essential for validating the probe's specificity and functional relevance in vascular and tumor imaging models. Reliable statistical analysis underpins confidence in early-stage target validation decisions.
How does independent variable isolation fit NIR-II imaging in discovery?
Isolating variables such as probe concentration, imaging time points, and filter selection allows teams to attribute imaging outcomes directly to HLY1 probe performance. This approach supports mechanistic de-risking and clarifies the biological impact of the probe in discovery-stage experiments.
What do quantitative dependent variable measurements enable in NIR-II imaging?
Quantitative measurements of fluorescence intensity and spatial distribution enable objective comparison of probe performance across conditions. These outputs support reproducibility, assay development, and data-driven advancement decisions in preclinical imaging workflows.
Why are replication requirements critical for cross-functional NIR-II imaging studies?
Replication ensures that imaging results with HLY1 are consistent and reproducible across different operators, instruments, and biological models. This reliability is vital for cross-functional collaboration and for translating imaging findings into actionable R&D insights.
What statistical analysis capabilities are required before NIR-II imaging implementation?
Robust statistical tools are needed to analyze fluorescence intensity, signal-to-noise ratios, and spatial resolution in NIR-II imaging datasets. These capabilities enable teams to validate probe performance, compare experimental groups, and support data-driven decision-making in biopharma research.
